Literature DB >> 19253275

Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.

Xiaodan Su1, David M Lucas, Liwen Zhang, Hua Xu, Vlad Zabrouskov, Melanie E Davis, Amy R Knapp, Donn C Young, Philip R O Payne, Mark R Parthun, Guido Marcucci, Michael R Grever, John C Byrd, Michael A Freitas.   

Abstract

The in vitro evaluation of histones and their PTMs has drawn substantial interest in the development of epigenetic therapies. The differential expression of histone isoforms may serve as a potential marker in the classification of diseases affected by chromatin abnormalities. In this study, protein profiling by LC and MS was used to explore differences in histone composition in primary chronic lymphocytic leukemia (CLL) cells. Extensive method validations were performed to determine the experimental variances that would impact histone relative abundance. The resulting data demonstrated that the proposed methodology was suitable for the analysis of histone profiles. In 4 normal individuals and 40 CLL patients, a significant decrease in the relative abundance of histone H2A variants (H2AFL and H2AFA/M*) was observed in primary CLL cells as compared to normal B cells. Protein identities were determined using high mass accuracy MS and shotgun proteomics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19253275      PMCID: PMC3108439          DOI: 10.1002/pmic.200800333

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  30 in total

1.  Automated reduction and interpretation of high resolution electrospray mass spectra of large molecules.

Authors:  D M Horn; R A Zubarev; F W McLafferty
Journal:  J Am Soc Mass Spectrom       Date:  2000-04       Impact factor: 3.109

2.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

Authors:  David G Oscier; Anne C Gardiner; Sarah J Mould; Sharron Glide; Zadie A Davis; Rachel E Ibbotson; Martin M Corcoran; Robert M Chapman; Peter W Thomas; J Adrian Copplestone; Jenny A Orchard; Terry J Hamblin
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

4.  Liquid chromatography mass spectrometry profiling of histones.

Authors:  Xiaodan Su; Naduparambil K Jacob; Ravindra Amunugama; David M Lucas; Amy R Knapp; Chen Ren; Melanie E Davis; Guido Marcucci; Mark R Parthun; John C Byrd; Richard Fishel; Michael A Freitas
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-01-07       Impact factor: 3.205

5.  Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.

Authors:  Stephan Stilgenbauer; Sandrine Sander; Lars Bullinger; Axel Benner; Elke Leupolt; Dirk Winkler; Alexander Kröber; Dirk Kienle; Peter Lichter; Hartmut Döhner
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

6.  Blood donor leukocyte reduction filters as a source of human B lymphocytes.

Authors:  J H Weitkamp; J E Crowe
Journal:  Biotechniques       Date:  2001-09       Impact factor: 1.993

7.  Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.

Authors:  Xiaodan Su; Liwen Zhang; David M Lucas; Melanie E Davis; Amy R Knapp; Kari B Green-Church; Guido Marcucci; Mark R Parthun; John C Byrd; Michael A Freitas
Journal:  Anal Biochem       Date:  2006-12-20       Impact factor: 3.365

8.  Global histone modifications predict prognosis of resected non small-cell lung cancer.

Authors:  Fabrice Barlési; Giuseppe Giaccone; Marielle I Gallegos-Ruiz; Anderson Loundou; Simone W Span; Pierre Lefesvre; Frank A E Kruyt; Jose Antonio Rodriguez
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

9.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Liguang Chen; George Widhopf; Lang Huynh; Laura Rassenti; Kanti R Rai; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry.

Authors:  Liwen Zhang; Michael A Freitas; Joseph Wickham; Mark R Parthun; Marko I Klisovic; Guido Marcucci; John C Byrd
Journal:  J Am Soc Mass Spectrom       Date:  2004-01       Impact factor: 3.109

View more
  11 in total

1.  High-sensitivity TFA-free LC-MS for profiling histones.

Authors:  Jia You; Liwen Wang; Motoyasu Saji; Susan V Olesik; Matthew D Ringel; David M Lucas; John C Byrd; Michael A Freitas
Journal:  Proteomics       Date:  2011-08       Impact factor: 3.984

2.  Age-related changes in mesenchymal stem cells derived from rhesus macaque bone marrow.

Authors:  Ji Min Yu; Xiying Wu; Jeffrey M Gimble; Xiaoyan Guan; Michael A Freitas; Bruce A Bunnell
Journal:  Aging Cell       Date:  2011-02       Impact factor: 9.304

Review 3.  Breaking the histone code with quantitative mass spectrometry.

Authors:  Laura-Mae P Britton; Michelle Gonzales-Cope; Barry M Zee; Benjamin A Garcia
Journal:  Expert Rev Proteomics       Date:  2011-10       Impact factor: 3.940

4.  AT1 receptor induced alterations in histone H2A reveal novel insights into GPCR control of chromatin remodeling.

Authors:  Rajaganapathi Jagannathan; Suma Kaveti; Russell W Desnoyer; Belinda Willard; Michael Kinter; Sadashiva S Karnik
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

5.  Histone variants and their post-translational modifications in primary human fat cells.

Authors:  Asa Jufvas; Peter Strålfors; Alexander V Vener
Journal:  PLoS One       Date:  2011-01-07       Impact factor: 3.240

6.  Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis.

Authors:  Rajbir Singh; Amir Mortazavi; Kelly H Telu; Prabakaran Nagarajan; David M Lucas; Jennifer M Thomas-Ahner; Steven K Clinton; John C Byrd; Michael A Freitas; Mark R Parthun
Journal:  Nucleic Acids Res       Date:  2013-08-16       Impact factor: 16.971

7.  Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults.

Authors:  Samantha R Renusch; Sean Harshman; Hongyang Pi; Eileen Workman; Allison Wehr; Xiaobai Li; Thomas W Prior; Bakri H Elsheikh; Kathryn J Swoboda; Louise R Simard; John T Kissel; Daniel Battle; Mark R Parthun; Michael A Freitas; Stephen J Kolb
Journal:  J Neuromuscul Dis       Date:  2015-06-04

8.  Histone isoform H2A1H promotes attainment of distinct physiological states by altering chromatin dynamics.

Authors:  Saikat Bhattacharya; Divya Reddy; Vinod Jani; Nikhil Gadewal; Sanket Shah; Raja Reddy; Kakoli Bose; Uddhavesh Sonavane; Rajendra Joshi; Duane Smoot; Hassan Ashktorab; Sanjay Gupta
Journal:  Epigenetics Chromatin       Date:  2017-10-18       Impact factor: 4.954

9.  Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.

Authors:  Rajbir Singh; Sean W Harshman; Amy S Ruppert; Amir Mortazavi; David M Lucas; Jennifer M Thomas-Ahner; Steven K Clinton; John C Byrd; Michael A Freitas; Mark R Parthun
Journal:  Clin Proteomics       Date:  2015-08-27       Impact factor: 3.988

Review 10.  Replication-dependent histone isoforms: a new source of complexity in chromatin structure and function.

Authors:  Rajbir Singh; Emily Bassett; Arnab Chakravarti; Mark R Parthun
Journal:  Nucleic Acids Res       Date:  2018-09-28       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.